Compare Diamondback Energy Inc (FANG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Viatris Inc — how do they compare? Diamondback Energy Inc trades at $190.23 (market cap $53.38B), while Viatris Inc trades at $17.29 (market cap $19.44B). The key difference: Diamondback Energy Inc is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| FANG | VTRS | |
|---|---|---|
Market Cap | $53.38B | $19.44B |
Sector | Energy | Health |
52-Week High | $213.69 | $17.39 |
52-Week Low | $134.53 | $8.74 |
Enterprise Value | $67.11B | $31.65B |
Dividend Yield | 2.32% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $190.69, showing slight daily weakness but maintaining a bullish technical outlook with strong analyst support. The company demonstrates solid revenue growth reaching $14.93B in 2025, though net margins have compressed to 1.88%. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending. The stock benefits from overwhelming analyst consensus with 90% buy ratings and a $234.50 price target representing 23% upside potential.
FANG presents a compelling growth story with expanding operations and strong cash generation, though investors face margin compression risks amid volatile energy markets. The stock's elevated P/E ratio of 193.63 reflects growth expectations, while technical indicators suggest near-term support around $189. Institutional sentiment remains positive with upcoming Q2 earnings on August 3, 2026, serving as the next key catalyst.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
